Skip to content
Cephaloglycin
Kafocin (cephaloglycin) is a small molecule pharmaceutical. Cephaloglycin was first approved as Kafocin on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cephaloglycin
Tradename
Company
Number
Date
Products
KAFOCINEli LillyN-050219 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
55 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Surgical wound infectionD013530111216
InfectionsD007239EFO_0000544111114
Urinary tract infectionsD014552EFO_0003103N39.0134
CellulitisD002481EFO_0003035L03.901113
Staphylococcal infectionsD013203A49.011112
OsteomyelitisD010019EFO_0003102M86112
Infectious arthritisD001170EFO_1001351M00112
Staphylococcal skin infectionsD013207EFO_1001849L0011
AbscessD000038EFO_000303011
FolliculitisD00549911
Show 8 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Nasal obstructionD015508HP_000174211
Nasal surgical proceduresD05974711
Systolic heart failureD054143EFO_1001207I50.2011
Sick sinus syndromeD012804EFO_0004275I49.511
SyncopeD013575HP_0001279G90.0111
Heart blockD006327I45.8911
Cystic fibrosisD003550EFO_0000390E8411
Cardiac arrhythmiasD001145EFO_0004269I49.911
Urinary bladder neoplasmsD001749C6711
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L2011
EczemaD004485HP_0000964L30.911
Skin diseasesD012871L00-L9911
DermatitisD003872HP_0011123L30.911
Genetic skin diseasesD01287311
Myeloid leukemia acuteD015470C92.0111
Breast neoplasmsD001943EFO_0003869C5011
Male breast neoplasmsD01856711
Genetic predisposition to diseaseD02002211
Pulmonary tuberculosisD014397EFO_1000049A1511
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients55
Respiratory tract infectionsD012141J06.933
PyomyositisD052880EFO_1001409M60.011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Dentofacial deformitiesD06316911
PharmacokineticsD01059911
Asymptomatic diseasesD05807011
Pregnancy complicationsD01124811
Soft tissue infectionsD01846111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEPHALOGLYCIN
INNcefaloglycin
Description
Cefaloglycin is a cephalosporin antibiotic containing at the 7beta-position of the cephem skeleton an (R)-amino(phenyl)acetamido group. It has a role as an antimicrobial agent. It is a cephalosporin and a beta-lactam antibiotic allergen.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
Identifiers
PDB
CAS-ID3577-01-3
RxCUI
ChEMBL IDCHEMBL1200971
ChEBI ID34613
PubChem CID19150
DrugBankDB00689
UNII IDHD2D469W6U (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 209 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7,324 adverse events reported
View more details